View CME-certified poster presentations and downloadable slides covering the most up-to-date clinical trial data on gastrointestinal (GI) cancers from the 2018 European Oncology Congress in Munich.
1.25 AMA PRA Category 1 Credit(s)™
Apr 15, 2019
Apr 15, 2020
Colorectal Cancer (CRC)
Abstract #LBA20: TRIBE2: a phase III, randomized strategy study by GONO in the 1st- and 2nd-line treatment of unresectable metastatic colorectal cancer (mCRC) patients (pts)
Featured Expert: Chiara Cremolini, MD
Abstract #LBA19: Fluoropyrimidine (FP) + bevacizumab (BEV) + atezolizumab vs FP/BEV in BRAFwt metastatic colorectal cancer (mCRC): Findings from Cohort 2 of MODUL – a multicentre, randomized trial of biomarker-driven maintenance treatment following first-line induction therapy
Featured Expert: Axel Grothey, MD
Abstract #463P: Real-world dosing of regorafenib (REG) in metastatic colorectal cancer (mCRC): Final results from the prospective, observational CORRELATE study
Featured Expert: Juan Manuel O’Conner, MD
Abstract #464P: Safety and efficacy of trifluridine/tipiracil (FTD/TPI) in metastatic colorectal cancer (mCRC) patients according to previous treatment with regorafenib in the international phase 3b PRECONNECT study
Featured Expert: Julien Taïeb, MD, PhD
Abstract #466P: Phase II trial to evaluate efficacy and tolerance of regorafenib monotherapy in patients (pts) over 70 with previously treated metastatic colorectal adenocarcinoma (mCRC) FFCD 1404 – REGOLD
Featured Expert: Thomas Aparicio, MD, PhD
Hepatocellular Carcinoma (HCC)
Abstract #710P: Practice patterns and deterioration of liver function after transarterial chemoembolization (TACE) in hepatocellular carcinoma (HCC): Final analysis of OPTIMIS in Europe and Canada
Featured Expert: Jean-Luc Raoul, MD, PhD
Abstract #LBA26: Updated safety and clinical activity results from a phase Ib study of atezolizumab + bevacizumab in hepatocellular carcinoma (HCC)
Featured Expert: Michael J. Pishvaian, MD, PhD
Thomas Aparicio, MD, PhDSaint Louis Hospital, AP-HP
Paris Diderot University
Chiara Cremolini, MDSanta Chiara Hospital
Axel Grothey, MDWest Cancer Clinic
Germantown, Tennessee, United States
Juan Manuel O’Conner, MDAlexander Fleming Institute (IAF)
Buenos Aires, Argentina
Michael J. Pishvaian, MD, PhDLombardi Comprehensive Cancer Center
Washington, DC, United States
Jean-Luc Raoul, MD, PhDInstitut de Cancérologie de l'Ouest
Saint Herblain, France
Julien Taïeb, MD, PhD Georges Pompidou European Hospital
This activity is specifically designed for physicians, nurses, and other clinicians who are cancer specialists.
After successful completion of this educational activity, participants should be able to:
- Identify clinical trial data presented at 2018 European Oncology Congress in Munich
- Incorporate new findings presented in Munich into patient treatment regimens, where applicable
This educational activity is supported by grants from Bayer HealthCare Pharmaceuticals, Inc.; Bristol-Myers Squibb; and Merck and Co, Inc.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine and prIME Oncology. Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity is jointly provided by Postgraduate Institute for Medicine and prIME Oncology.
Method of Participation
Estimated time to complete activity: 1.25 hours
To contact Postgraduate Institute for Medicine please visit www.pimed.com.
Disclosure of Relevant Financial Relationships
Postgraduate Institute for Medicine (PIM) and prIME Oncology require instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to PIM policy. PIM is committed to providing its learners with high quality activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.
The faculty reported the following financial relationships or relationships to products or devices they or their spouses/life partners have with commercial interest related to the content of this activity:
Dr Aparicio has disclosed that he worked on conferences for Amgen, Bristol-Meyers Squibb, Roche, Sanofi, and Servier. He received congress grants from Ipsen, Novartis, and Roche. He disclosed research grants from Bayer, Merck, and Novartis. He received consulting fees from Bristol-Meyers Squibb and Ipsen. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Cremolini has disclosed advisory boards with Bayer. She received consulting fees from Amgen, Roche, and Servier. Furthermore, she has been speaking and teaching for Servier. She has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in her presentation.
Dr Grothey has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr O’Connor has no relevant financial relationships to disclose. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Pishvaian has disclosed honoraria for speaker’s bureaus from Caris, Celgene, and Sirtex. He also disclosed advisory board meeting participation for ARMO, Eisai, Ignyta, Ipsen, Merrimack, and Rafael. He also has stock options with Perthera. He also disclosed receipt of research support for his institution from AbbVie, ARMO, AstraZeneca, Bavarian Nordic, Bayer, Boston Biomedical, Bristol-Myers Squibb, Calithera, Celldex, Celgene, Curegenix, Fibrogen, Genentech, Halozyme, Karyopharm, MedImmune, Merck, Novartis, Pfizer, Pharmacyclics, Regeneron, and Tesaro. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Raoul has disclosed board membership with Bayer, Ipsen, and Terumo. He also received honorarium for a promotional speaker’s bureau for Bayer. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Dr Taїeb has disclosed advisory boards with, receipt of consulting fees from, and honorarium for a promotional speaker’s bureau from Servier. He has agreed to disclose any unlabeled/unapproved uses of drugs or products referenced in his presentation.
Postgraduate Institute for Medicine Planners and Managers have disclosed no relevant financial relationships.
The employees of prIME Oncology have disclosed:
- Angela Zimmermann, PhD (scientific content manager) – worked on non–CME certified projects in the last 12 months supported by AstraZeneca, Merck, Novartis, and Pfizer
- Susan McKinney (editorial content reviewer) – no relevant financial relationships
Disclosure Regarding Unlabeled Use
This activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration or European Medicines Agency. Please refer to the official prescribing information for each product discussed for discussions of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.